Search Article Keyword:  

PubMed Submission Abstract PDF Feed Back Count: 3584 Download Count: 1526 

ISSN 1007-9327 CN 14-1219/R  World J Gastroenterol  2008 September 7; 14(33): 5154-5161

TOPIC HIGHLIGHT

Mucosal cytokine network in inflammatory bowel disease

Akira Andoh, Yuhki Yagi, Makoto Shioya, Atsushi Nishida, Tomoyuki Tsujikawa, Yoshihide Fujiyama


Akira Andoh, Yuhki Yagi, Makoto Shioya, Atsushi Nishida, Tomoyuki Tsujikawa, Yoshihide Fujiyama, Department of Medicine, Shiga University of Medical Science, Seta-Tukinowa, Otsu 520-2192, Japan

Author contributions: Andoh A and Fujiyama Y designed the research; Yagi Y, Shioya M, Nishida A and Tsujikawa T performed the research; and Andoh A wrote the paper.

Correspondence to: Akira Andoh, MD, PhD, Department of Internal Medicine, Shiga University of Medical Science, Seta-Tukinowa, Otsu 520-2192, Japan. andoh@belle.shiga-med.ac.jp

Telephone: +81-77-5482217  Fax: +81-77-5482219

Received: April 10, 2008       Revised: May 23, 2008

Accepted: May 30, 2008

Published online: September 7, 2008

  

Abstract

Inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn’s disease (CD) are characterized by ongoing mucosal inflammation in which dysfunction of the host immunologic response against dietary factors and commensal bacteria is involved. The chronic inflammatory process leads to disruption of the epithelial barrier, and the formation of epithelial ulceration. This permits easy access for the luminal microbiota and dietary antigens to cells resident in the lamina propria, and stimulates further pathological immune cell responses. Cytokines are essential mediators of the interactions between activated immune cells and non-immune cells, including epithelial and mesenchymal cells. The clinical efficacy of targeting TNF-a clearly indicates that cytokines are the therapeutic targets in IBD patients. In this manuscript, we focus on the biological activities of recently-reported cytokines [Interleukin (IL)-17 cytokine family, IL-31 and IL-32], which might play a role through interaction with TNF-a in the pathophysiology of IBD.

 

© 2008 The WJG Press. All rights reserved.

 

Key words: Cytokine; Inflammatory bowel disease; Interleukin-17; Interleukin-31; Interleukin-32

 

Peer reviewers: Dr. Francesco Costa, Dipartimento di Medicina Interna-U.O. di Gastroenterologia Università di Pisa, Via Roma, Pisa 67-56122, Italy; Kiron M Das, MD, PhD, FACP, FRCP, Chief of Gastroenterology and Hepatology, Professor of Medicine, Director of Crohn’s and Colitis Center of NJ, 1 Robert Wood Johnson Place, MEB Rm. 478, New Brunswick, NJ 08903, United States

 

Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y. Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 2008; 14(33): 5154-5161  Available from: URL: http://www.wjgnet.com/1007-9327/14/5154.asp  DOI: http://dx.doi.org/10.3748/wjg.14.5154

  

INTRODUCTION

Inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease (CD) are chronic intestinal disorders of unknown etiology[1,2]. The most widely accepted hypothesis on the pathogenesis of IBD is that the mucosal immune system shows an aberrant response towards luminal antigens such as dietary factors and/or commensal bacteria in genetically susceptible individuals[1,3,4]. Environmental factors may also precipitate the onset or reactivation of this disease[1,3,4]. The chronic inflammatory process leads to disruption of the epithelial barrier, and the formation of epithelial ulceration. Abnormal bacterial killing based on genetic factors such as the NOD2 gene mutation also induces mucosal damage. The easy access for the luminal microbiota and dietary antigens into cells resident in the lamina propria thus stimulates pathological immune cell responses.

Cytokines are essential mediators of the interactions between activated immune cells and non-immune cells, including epithelial and mesenchymal cells[5]. The clinical efficacy of targeting TNF-a clearly indicates that cytokines are one of the therapeutic targets of chronic inflammatory disorders such as IBD. Infliximab, a mouse/human chimeric mAb that binds to TNF-a, has shown efficacy in the treatment of moderate-to severe CD and a number of CD-related complications[6-8]. Although the precise mechanism of the action of infliximab is not clear, it neutralizes soluble TNF-a, alters cell signaling, and induces the apoptosis of activated inflammatory cells expressing surface TNF-a via multiple pathways. On the other hand, some patients are resistant to anti-TNF-a therapy. In such patients, the disease might be driven by molecular mechanisms dependent on other cytokines distinct from TNF-a. In this manuscript, we focused on recently-reported cytokines [Interleukin (IL)-17 cytokine family, IL-31 and IL-32] which might play a role through interactions with TNF-a in the pathophysiology of IBD.

 

IL-17 CYTOKINE FAMILY

IL-17 family and Th17 cells

The interleukin (IL)-17 cytokine family is a group of T cell derived cytokines. IL-17A was originally cloned by Rouvier et al[9] and named CTLA8. It was subsequently renamed IL-17, and was more recently termed IL-17A. IL-17A stimulates various cell types to secrete various cytokines and chemokines, resulting in the induction of inflammation[10-15]. The IL-17 family may play a role in a number of diseases mediated by abnormal immune responses, such as rheumatoid arthritis[16,17], pulmonary disease[15,18], lupus[19], multiple sclerosis[20], and IBD[21]. Homology-based cloning recently revealed five additional members of the IL-17 family, termed IL-17B to IL-17F[10]. Among the IL-17 family members, IL-17F has the highest degree of homology with IL-17A (40% to 55%), followed by IL-17B (29%), IL-17D (25%), IL-17C (23%), and IL-17E (also named IL-25) is the most distantly related (17%)[10]. The major cellular source of IL-17A was initially described as activated CD4+ memory T lymphocytes. But, it was subsequently demonstrated that CD8+ memory T lymphocytes, eosinophils, neutrophils and monocytes can also produce IL-17A[10,22]. The cellular sources of IL-17B and IL-17C have not been identified. IL-17D is derived from resting CD4+ T cells and CD19+ B cells[15]. But, IL-17E (IL-25) expression is restricted to Th2 cells and mast cells[15]. The cellular source of the last member, IL-17F, has been reported to be activated CD4+ T cells, basophils and mast cells[15].

One recent topic in immunology is the newly identified Th17 lineage of CD4+ T cells[23]. Th17 cells are characterized by the production of a distinct profile of effector cytokines, including IL-17A, IL-17F, IL-6, IL-22 and IL-26, and have probably evolved to enhance immune and host defense responses distinct from those targeted by Th1 and Th2 cells[24-26]. Th17 cells develop from naïve CD4 T cell precursors in the presence of IL-6 and TGF-b, and full differentiation to Th17 cells is dependent on IL-23[23]. Recent studies demonstrated a role for IL-21 in Th17 development[24,27]. IL-21 serves as an autocrine factor secreted by Th17 cells that promotes or sustains the Th17 lineage commitment. On the other hand, Th1 cells develop from naïve CD4 T cell precursors in the presence of IFN-g, whereas Th2 cells develop under the control of IL-4. Both IFN-g and IL-4 inhibit Th17 cell proliferation[28]. A recent study showed that the proliferation of Th17 cells is also inhibited by IL-27, an IL-12-related cytokine frequently present at sites of inflammation[29]. Th17 cells are characterized as a source of IL-17A and IL-17F, and much attention has been focused on their functions in normal and pathological immune responses.

We previously demonstrated that IL-17A-positive cells were increased in the inflamed mucosa of IBD patients[21], and a recent study showed that IL-17F mRNA expression in the mucosa was elevated in CD patients[30]. These observations suggest that IL-17F as well as IL-17A might play a role in the inflammatory responses involved in the pathophysiology of IBD.

 

Inflammatory responses induced by IL-17A and IL-17F

IL-17A promotes the expansion and recruitment of innate immune cells such as neutrophils, and also cooperates with TLR ligands, IL-1b, and TNF-a to enhance inflammatory reactions, and to stimulate the production of beta-defensins and other antimicrobial peptides[25,27]. Its receptor, IL-17RA, is ubiquitously expressed and shares many features with classical innate immune receptors such as shared intracellular tail motifs and convergence onto common inflammatory transcription pathways[31]. To investigate the genes altered in response to an IL-17A stimulus, we performed a cDNA microarray analysis in human colonic subepithelial myofibroblasts (SEMFs)[32]. Human colonic SEMFs are located immediately subjacent to the basement membrane in the normal intestinal mucosa, juxtaposed against the bottom of the epithelial cells[33,34], and play a role in inflammation and wound healing in the intestine[33-36]. As shown in Table 1, IL-17A up-regulated several genes which have been reported to exert pro-inflammatory actions in the pathophysiology of acute and/or chronic inflammation. In particular, the induction of CXC-chemokines mRNA expression suggests that IL-17A is a potent inducer of innate immune responses via the accumulation and activation of neutrophils in the mucosa.

Recently, we found that among the IL-17 family members, IL-17F also strongly induced the secretion of inflammatory cytokines (IL-6, IL-8 and LIF) and matrix metalloproteinases (MMP-1 and MMP-3) in human colonic SEMFs[32]. Like IL-17A[37], IL-17F stimulated IL-6, IL-8 and MCP-1 secretion via NF-kB and MAP kinase activation in human colonic SEMFs. The IL-6, IL-8 and LIF secretion by human SEMFs in response to IL-17F as well as IL-17A emphasizes the importance of Th17 products in the induction of intestinal inflammation. Furthermore, the induction of IL-6 secretion from colonic SEMFs has a particular significance in the regulation of immune responses, and in the pathophysiology of IBD; IL-6 has recently been identified as an indispensable factor for the development of Th17 cells[23]. IL-6 commits naïve CD4 T cell precursors to differentiate into Th17 cells[23]. IL-17A and IL-17F might function as potent stimulators for IL-6 production, suggesting an amplification loop for the local development and maturation of Th17 cells. Therefore, the IL-17-colonic SEMFs-IL-6 axis may be important for local Th17 development in the intestinal mucosa.

 

IL-17A/IL-17F augments TNF-a-induced inflammatory responses

As more important observations, IL-17A and IL-17F augment the TNF-a-induced IL-6 secretion in human colonic SEMFs[32,37]. This augmentation of TNF-a-induced IL-6 production by IL-17A is mediated by enhanced stability of the IL-6 mRNA[37,38]. A similar molecular mechanism can be postulated for the augmentation by IL-17F. IL-17A/IL-17F also augments the TNF-a-induced expression of granulocyte-colony stimulating factor (G-CSF) and granulocyte/macrophage (GM)-CSF in human colonic SEMFs[39].

To further investigate the effects of IL-17A/IL-17F on TNF-a-induced genes, the alterations in gene expression were analyzed by cDNA microarrays in human colonic myofibroblasts. As shown in Table 2, IL-17A further enhanced the expression of various TNF-a-induced genes, such as IL-6, CXC-chemokines and CSFs. These observations suggest that the interactions between TNF-a and IL-17A/IL-17F potently mobilized neutrophils, partially through granulopoiesis and CXC chemokine induction, as well as through increased survival locally. This interaction also potently stimulated Th17 development through the stimulation of IL-6 secretion. Thus, a modulation of the immunological functions of colonic SEMFs by Th17-derived cytokines may be critical for the development of Th17 cells and the mucosal innate immune responses (Figure 1).

 

Interactions between IL-17A and IL-22

IL-22 was originally described as an IL-9-induced gene, and was termed “IL-10-related T cell-derived-inducible factor” (IL-TIF)[40,41]. IL-22 has 22% amino acid identity with IL-10, and belongs to a family of cytokines with limited homology to IL-10, namely IL-19, IL-20, IL-22, IL-24 and IL-26. The major sources of IL-22 are activated T cells, and IL-22 expression in other leukocyte populations such as monocytes, dendritic cells, NK cells and neutrophils is negligible. Recent studies have shown that Th17 cells are a source of IL-22[42,43]. We recently found that IL-22 expressing cells were increased in the inflamed mucosa of IBD patients[44]. In SEMFs, IL-22 upregulates the expression of inflammatory genes such as IL-6, IL-8, IL-11 and LIF via NF-kB, AP-1 and MAP-kinase dependent pathways[44]. Furthermore, the combination of IL-17A plus IL-22 showed an additive effect on transcription factor activation. These concerted responses were also observed as additive effects on cytokine mRNA expression and protein secretion. Thus, the cooperation between Th17 derived cytokines such as IL-17A and IL-22 may play an important role in the pathophysiology of IBD.

 

IL-31

IL-31 has a Th2 cell origin

IL-31 was cloned, and then found to be mainly produced by CD4+ T cells[45], in particular by skin-homing CD45RO+ (memory) T cells. Transgenic mice overexpressing IL-31 either with a lymphocyte-specific promoter or a ubiquitous promoter exhibit a skin phenotype closely resembling atopic dermatitis in human subjects[45]. In these mice, IL-31 seems to be preferentially produced by T cells skewed towards a Th2 phenotype; however, these Th1-skewed T cells also produce substantial amounts of IL-31[45]. IL-31 mRNA expression is widely detected in various organs, including the gastrointestinal tract[45].

IL-31 is most closely related to the family of IL-6-type cytokines known to be involved in many immunomodulatory functions, particularly the acute-phase response, but also in the proliferation of B and T cells[46]. A recent study indicated that IL-31 sustains the survival of hematopoietic stem cells, and contributes to effects on the cycling and numbers of hematopoietic stem cells in vivo[47]. However, IL-31 is clearly distinct from the IL-6-type cytokines because it does not signal through glycoprotein-130 (GP-130), the common signaling receptor subunit. IL-31 uses an earlier described orphan receptor, the glycoprotein 130-like monocyte receptor or glycoprotein 130-like receptor (GPL)[48], in combination with the oncostatin M receptor (OSMR)[45], which is expressed on epithelial cells and keratinocytes[45,49].

IL-31 binds directly to the GPL, and OSMR mainly plays a role in delivering the signaling information into the cells. GPL and OSMR are widely expressed in various tissues, including the gastrointestinal tract. This suggests a role for IL-31 in the immune and inflammatory responses of the intestine. In response to IL-31, its receptor complex recruits the Jak1, Jak2, STAT-1, STAT-3 and STAT5 signaling pathways, as well as the PI3-kinase/AKT cascade[49]. SHP-2 and Shc adaptor molecules are also recruited, and contribute to an increased activation of the MAP kinase pathway in response to IL-31[49]. Despite the extensive study of intracellular signaling pathways activated by IL-31 stimulation, the cellular responses to IL-31 were barely investigated in any cell type.

 

IL-31 stimulates inflammatory responses in colon myofibroblasts

To define the role of IL-31 in the intestinal mucosa, we investigated how IL-31 modulates mRNA expression in human colonic SEMFs. An analysis of the cDNA microarrays indicated that IL-31 effectively induced the secretion of chemokines [CXCL8 (IL-8), CXCL1 (growth-related oncogene; GRO-a)], CCL7 (monocyte chemoattractant protein-3; MCP-3), CXCL3, CCL13, CCL15), proinflammatory cytokines (IL-6, IL-16 and IL-32), and matrix metalloproteinases (MMP-1, MMP-3, MMP-25 and MMP-7). The stimulatory effects of IL-31 were comparable to the effects of IL-17A. Furthermore, simultaneous stimulation with IL-31 and IL-17A showed additive effects on IL-6, IL-8, GRO-a, MCP-3, MMP-1 and MMP-3 secretion. Similar effects for IL-31 have been reported in bronchial epithelial cells[50]. In bronchial epithelial cells, IL-31 could significantly elevate both gene and protein expressions of epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and monocyte chemoattractant protein-1 (MCP-1/CCL2). The combination of IL-31 with either IL-4 or IL-13 further enhanced VEGF and CCL2 production. In these cells, IL-31 could activate p38 MAPK, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK).

As mentioned above, IL-31 is a Th2 type cytokine, and these findings indicate that Th2 cells may be involved in the immune and inflammatory responses of the intestinal mucosa through IL-31secretion. Since IL-31 and IL-17A stimulate the secretion of proinflammatory mediators in an additive manner, Th2-derived IL-31 and Th17-derived IL-17A cooperate in the pathophysiology of IBD.

 

IL-32

IL-32 cytokine family

IL-32 is a recently described cytokine produced by T lymphocytes, natural killer cells, monocytes, and epithelial cells[51,52]. IL-32 is a proinflammatory cytokine originally described as a transcript termed NK4, found in activated natural killer (NK) cells and T lymphocytes[53]. Although IL-32 was first reported as a transcript in IL-2 activated NK and T cells, it appears that the epithelial cells are the dominant and widespread source[54]. The gene encoding IL-32 is located on human chromosome 16p13.3, and is organized into eight exons[55]. There are four splice variants (IL-32a, IL-32b, IL-32δ and IL-32g), and IL-32a is the most abundant transcript. Of particular importance, IL-32 is prominently induced by interferon (IFN)-g in lung epithelial cells and monocytes[51]. IL-32 stimulates the secretion of proinflammatory cytokines and chemokines such as IL-1b, TNF-a, IL-6 and IL-8 by via the activation of NF-kB and p38 mitogen-activated protein kinases (MAPKs)[51,52]. IL-32 has been implicated in inflammatory disorders such as rheumatoid arthritis[54,56-58], mycobacterium tuberculosis infection[59,60], and IBD[61].

 

Intracellular accumulation of IL-32

The amino acid sequence derived from the initial NK4 cDNA contained a signal peptide without a transmembrane domain[53,54]. But, the transcript was never expressed as a recombinant protein, and was not sequenced. Activated human T cells generate IL-32 with a molecular weight of 25 kDa, which on Western blotting analysis is found in the lysates rather than the supernatants. Similar findings were reported for 293T cells transfected with either IL-32g or IL-32b[62]. In human peripheral blood mononuclear cells stimulated with ConA, most of the IL-32 was found in the lysates[51]. On the other hand, the overexpression of IL-32a or IL-32b in COS cells resulted in secreted IL-32[51]. It remains unclear which isoforms are secreted from which particular cell type. Activated T cells and NK cells do not secrete IL-32, or alternatively, the secreted IL-32 is derived from apoptotic cells due to the presence of GAPDH in the same supernatants. These observations suggest that IL-32 is secreted only as a result of cell death[63]. Recently, we observed that in colon cancer cell lines, proinflammatory cytokines induce the intracellular accumulation of IL-32a, but does not induce secretion[61]. Similar results were also observed in myofibroblasts isolated from the normal human pancreas[64]. Goda et al suggest that there is a role for intracellular IL-32 with cell death, since attenuating intracellular IL-32 levels resulted in decreased cell death[62]. These results also support the concept that high levels of intracellular IL-32b may induce cell death. One hypothesis is that the proinflammatory activity of IL-32 may act upon its release through cell death (apoptosis).

 

Molecular mechanisms regulating IL-32a induction

Shioya et al demonstrated that stimulation with IL-1b, IFN-g and TNF-a enhanced IL-32a mRNA expression in three colon cancer cell lines[61]. TNF-a was the strongest among them. These factors also induced the intracellular accumulation of IL-32a. Since transfection with the mutant form of IkBa inhibited the effects of both IL-1b and TNF-a on IL-32a mRNA expression, NF-kB must play a role in IL-1b- and TNF-a-induced IL-32a mRNA expression.

Nishida et al analyzed IL-32a expression in non-transformed myofibroblasts derived from the normal human pancreas[64]. IL-32a mRNA was weakly expressed without any stimulus, and its expression was markedly enhanced by IL-1b, IFN-g and TNF-a. IL-1b, IFN-g and TNF-a enhanced the intracellular accumulation of IL-32a protein. But, IL-32a was not detected in the supernatants. An inhibitor of phosphatidylinositol 3-kinase, (LY294002) significantly suppressed the IL-1b-, IFN-g- and TNF-a-induced IL-32a mRNA expression, although MAPK inhibitors had no effect. Akt activation in response to these cytokines was confirmed by Western blotting analysis. Furthermore, LY294002 suppressed both IL-1b- and TNF-a-induced NF-kB activation, as well as IL-1b-, TNF-a- and IFN-g-induced AP-1 activation. A blockade of NF-kB and AP-1 activation by an adenovirus expressing a stable mutant form of IkBa and a dominant negative mutant of c-Jun markedly suppressed the IL-1b-, IFN-g- and/or TNF-a-induced IL-32a mRNA expression. Thus, they concluded that IL-32a mRNA expression was dependent on interactions between the PI3K/Akt-pathway and the NF-kB/AP-1 system.

 

IL-32a and IBD

Shioya et al performed an immunohistochemical analysis to evaluate the expression of IL-32a protein in the mucosa of IBD patients[61]. IL-32a was weakly immunoexpressed by epithelial cells in the normal colonic mucosa and samples of ischemic colitis. In contrast, the epithelial expression of IL-32a was markedly enhanced in the inflamed region of active UC and CD patients[61]. In particular, IL-32a expression tends to increase in samples from active CD patients. IL-32a expression was barely detectable in leukocytes. Thus, these observations indicate that epithelial cells are the major expression site for IL-32a in the intestinal mucosa, and that IL-32a expression is enhanced in the IBD mucosa.

Netea et al recently demonstrated that IL-32 augments the production of IL-1b and IL-6 induced by muramyl dipeptide (MDP), a peptidoglycan fraction of bacteria, by means of nucleotide-binding oligomerization domain proteins (NOD1 and NOD2) through a caspase-1-dependent mechanism[52]. NODs are a family of intracytoplasmic bacterial sensors, and the recognition of bacterial peptidoglycans subsequently induces NF-kB activation[65]. Mutations in NOD2 have been implicated in the pathogenesis of CD[66,67], and CD patients homozygous for the frameshift 3020insC mutated allele have defective responses to MDP in terms of cytokine production[68,69]. Recently, it has been shown that NOD2 mutations in CD patients potentiate NF-kB activity and IL-1b processing[70]. Thus, these findings suggest a pivotal role for IL-32 in the pathophysiology of IBD, and in particular CD. Since IL-32a is a proinflammatory cytokine characterized by NF-kB and p38 MAPK activating activities[51,57] and because IL-32 acts synergistically with NOD ligands to induce proinflammatory cytokines[52], the overexpression of IL-32a in the IBD mucosa strongly suggests that it plays an important role in the inflammatory and antibacterial responses involved in the pathogenesis of IBD.

Recent studies have focused on the role of innate immunity in the pathogenesis of IBD[4]. The initial step of innate immunity is mediated by the recognition of pathogen-associated molecular patters (PAMPs) through Toll-like receptors (TLRs) and NOD proteins (NODs)[71]. TLRs are located mainly on cell-surface membranes, but NODs function as intracellular recognition systems[65,66]. In human monocytes, IL-32 acts synergistically with NOD specific peptidoglycans for the release of IL-1b and IL-6[52]. The synergistic effects of IL-32 and the NOD ligands on cytokine production is abolished in cells from CD patients bearing the NOD2 frameshift mutation 3020insC, indicating that this synergism between IL-32 plus MDP depends on NOD2[52]. Interactions between NOD-1 and IL-32 also potentiate proinflammatory cytokine production[52]. Furthermore, Berrebi et al previously reported the overexpression of NOD2 in infiltrated monocytes and epithelial cells in the IBD mucosa[72]. These observations suggest that overexpressed IL-32 may cause a specific and excessive stimulation of the NOD pathways, which leads to a marked amplification in IL-1b and IL-6 production in the IBD mucosa.

IL-32 was initially characterized as an inducer of TNF-a in circulating monocytes[51], and hence inflammatory responses in the affected mucosa of IBD patients may be amplified by the consecutive loop of IL-32-induced TNF-a secretion from monocytes and TNF-a-stimulated IL-32 secretion from epithelial cells. This loop may be further amplified by the Th1 cytokine IFN-g. Previously, it has been reported that TNF-a and IFN-g synergistically induced the release of NOD2[73], which supports the coupled regulation of IL-32a and NOD2. The coupled regulation of IL-32a with NOD2 may account for the rapid and efficient induction of innate immune responses at the intestinal mucosa. Furthermore, these data suggest that an amelioration of IBD symptoms by TNF-a-targeting therapies may be partially dependent on interference in the TNF-a-IL-32 loop.

The apoptosis of IECs is considered a normal biological function to eliminate damaged epithelial cells, and to restore epithelial cell growth, regulation, and epithelial integrity[74]. An overexpression of cytoplasmic IL-32a might account for the induction of apoptosis in damaged epithelial cells at the inflamed mucosa of IBD patients, leading to an efficient elimination and the rapid induction of mucosal repair. Apoptosis caused by accumulated IL-32 can be considered a host defense mechanism against invading microorganisms, in which damaged epithelial cells are efficiently eliminated along with the invading microorganisms, and thus any further invasion of the microorganisms can be blocked.

 

CONCLUSION

In this review, we have summarized the newly reported cytokines which may play significant roles in the pathophysiology of IBD. An augmentation of TNF-a effects by IL-17A/F and a possible amplifying cascade between TNF-a and epithelial-derived IL-32 are of particular interest. The clinical efficacy of TNF-a blocking may be associated with an interruption of these cascades. The discovery of new cytokines and the determination of their biological activities may support the development of a novel therapeutic strategy for the treatment of IBD patients.

 

REFERENCES

1      Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J
        Gastroenterol
2008; 43: 1-17  
PubMed   DOI

2      Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007; 42: 16-25   PubMed   DOI

3      Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429   PubMed   DOI

4      Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol
        Hepatol
2006; 3: 390-407  
PubMed   DOI

5      Fantini MC, Monteleone G, Macdonald TT. New players in the cytokine orchestra of inflammatory bowel disease.
        Inflamm Bowel Dis
2007; 13: 1419-1423  
PubMed   DOI

6      Panes J, Gomollon F, Taxonera C, Hinojosa J, Clofent J, Nos P. Crohn's disease: a review of current treatment with a
        focus on biologics. Drugs 2007; 67: 2511-2537  
PubMed   DOI

7      Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in
        Crohn‘s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007; 26: 1509-1520  
PubMed   DOI

8      Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies.
        Lancet
2007; 369: 1641-1657  
PubMed   DOI

9      Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich
        messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993; 150: 5445-5456

        PubMed 

10    Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-476   PubMed   DOI

11    Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ. Human IL-17: a novel cytokine derived
        from T cells. J Immunol 1995; 155: 5483-5486  
PubMed  

12    Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S,
        Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, Lebecque S. T cell interleukin-17 induces
        stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183: 2593-2603  
PubMed   DOI

13    Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK. Herpesvirus Saimiri
        encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3: 811-821  
PubMed   DOI

14    Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP. IL-17 stimulates the
        production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol
        1998; 160: 3513-3521  
PubMed  

15    Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. J Allergy Clin Immunol 2004; 114: 1265-
        1273; quiz 1274  
PubMed   DOI

16    Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin
        TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J
        Clin Invest
1999; 103: 1345-1352  
PubMed   DOI

17    Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W. High
        levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive
        mechanism. J Immunol 2000; 164: 2832-2838  
PubMed   DOI

18    Kawaguchi M, Takahashi D, Hizawa N, Suzuki S, Matsukura S, Kokubu F, Maeda Y, Fukui Y, Konno S, Huang SK,
        Nishimura M, Adachi M. IL-17F sequence variant (His161Arg) is associated with protection against asthma and
        antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 2006; 117: 795-801  
PubMed   DOI

19    Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4)
        concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9: 589-593  
PubMed   DOI

20    Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, Takabayashi K, Iwamoto I. Increased interleukin-17
        production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-2463  
PubMed   DOI

21    Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in
        inflammatory bowel disease. Gut 2003; 52: 65-70  
PubMed   DOI

22    Shin HC, Benbernou N, Esnault S, Guenounou M. Expression of IL-17 in human memory CD45RO+ T lymphocytes and its
        regulation by protein kinase A pathway. Cytokine 1999; 11: 257-266  
PubMed   DOI

23    Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T
        cell ties. Immunity 2006; 24: 677-688  
PubMed   DOI

24    Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007; 19: 652-
        657  
PubMed   DOI

25    Stockinger B, Veldhoen M, Martin B. Th17 T cells: linking innate and adaptive immunity. Semin Immunol 2007; 19:
        353-361  
PubMed   DOI

26    Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol 2007; 19: 377-382   PubMed   DOI

27    Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F,
        Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R. Development, cytokine profile and
        function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-957  
PubMed   DOI

28    Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116: 1218-1222   PubMed   DOI

29    Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE. TH17 cells contribute to
        uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13: 711-718  
PubMed   DOI

30    Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, Pfennig S, Jurgens M, Schmechel S, Konrad A, Goke B,
        Ochsenkuhn T, Muller-Myhsok B, Lohse P, Brand S. Role of the novel Th17 cytokine IL-17F in inflammatory bowel
        disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg
        polymorphism in IBD. Inflamm Bowel Dis 2008; 14: 437-445   PubMed   DOI

31    Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, Tocker J, Peschon J. Cutting edge: interleukin 17 signals
        through a heteromeric receptor complex. J Immunol 2006; 177: 36-39  
PubMed   DOI

32    Yagi Y, Andoh A, Inatomi O, Tsujikawa T, Fujiyama Y. Inflammatory responses induced by interleukin-17 family
        members in human colonic subepithelial myofibroblasts. J Gastroenterol 2007; 42: 746-753  
PubMed   DOI

33    Andoh A, Bamba S, Fujiyama Y, Brittan M, Wright NA. Colonic subepithelial myofibroblasts in mucosal inflammation and
        repair: contribution of bone marrow-derived stem cells to the gut regenerative response. J Gastroenterol 2005; 40:
        1089-1099  
PubMed   DOI

34   Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. II. Intestinal subepithelial
        myofibroblasts. Am J Physiol 1999; 277: C183-C201  
PubMed  

35    Mahida YR, Beltinger J, Makh S, Goke M, Gray T, Podolsky DK, Hawkey CJ. Adult human colonic subepithelial
        myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2. Am J Physiol 1997; 273: G1341-
        G1348   PubMed  

36    Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health
        and disease. Am J Physiol 1999; 277: C1-C9  
PubMed  

37    Hata K, Andoh A, Shimada M, Fujino S, Bamba S, Araki Y, Okuno T, Fujiyama Y, Bamba T. IL-17 stimulates
        inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol
        Gastrointest Liver Physiol
2002; 282: G1035-G1044  
PubMed   DOI

38    Shimada M, Andoh A, Hata K, Tasaki K, Araki Y, Fujiyama Y, Bamba T. IL-6 secretion by human pancreatic periacinar
        myofibroblasts in response to inflammatory mediators. J Immunol 2002; 168: 861-868  
PubMed  

39    Andoh A, Yasui H, Inatomi O, Zhang Z, Deguchi Y, Hata K, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi
        A, Shimizu N, Fujiyama Y. Interleukin-17 augments tumor necrosis factor-alpha-induced granulocyte and
        granulocyte/macrophage colony-stimulating factor release from human colonic myofibroblasts. J Gastroenterol 2005;
        40: 802-810  
PubMed   DOI

40    Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity
        2004; 21: 241-254  
PubMed   DOI

41    Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H. The interleukin-10 family of cytokines. Trends
        Immunol
2002; 23: 89-96  
PubMed   DOI

42    Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. Interleukin (IL)-22 and IL-17
        are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203:
        2271-2279  
PubMed   DOI

43    Chen Z, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008; 41: 87-102  PubMed  
       
DOI

44    Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A,
        Shimizu N, Fujiyama Y. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic
        subepithelial myofibroblasts. Gastroenterology 2005; 129: 969-984  
PubMed   DOI

45    Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B,
        Johnston J, Bort S, Mudri S, Kuijper JL, Bukowski T, Shea P, Dong DL, Dasovich M, Grant FJ, Lockwood L, Levin SD,
        LeCiel C, Waggie K, Day H, Topouzis S, Kramer J, Kuestner R, Chen Z, Foster D, Parrish-Novak J, Gross JA. Interleukin
        31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 752-760  
PubMed   DOI

46    Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the
        gp130/Jak/STAT pathway. Biochem J 1998; 334 (Pt 2): 297-314  
PubMed  

47    Broxmeyer HE, Li J, Hangoc G, Cooper S, Tao W, Mantel C, Graham-Evans B, Ghilardi N, de Sauvage FJ. Regulation of
        myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31. Exp Hematol 2007; 35: 78-86  
PubMed   DOI

48    Ghilardi N, Li J, Hongo JA, Yi S, Gurney A, de Sauvage FJ. A novel type I cytokine receptor is expressed on monocytes,
        signals proliferation, and activates STAT-3 and STAT-5. J Biol Chem 2002; 277: 16831-16836  
PubMed   DOI

49    Diveu C, Lak-Hal AH, Froger J, Ravon E, Grimaud L, Barbier F, Hermann J, Gascan H, Chevalier S. Predominant
        expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur Cytokine Netw
       
2004; 15: 291-302  
PubMed 

50    Ip WK, Wong CK, Li ML, Li PW, Cheung PF, Lam CW. Interleukin-31 induces cytokine and chemokine production from
        human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications
        for the allergic response. Immunology 2007; 122: 532-541  
PubMed   DOI

51    Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005;
        22: 131-142  
PubMed   DOI

52    Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA, Kim SH. IL-
        32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production
        through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 2005; 102: 16309-16314  
PubMed   DOI

53    Dahl CA, Schall RP, He HL, Cairns JS. Identification of a novel gene expressed in activated natural killer cells and T cells.
        J Immunol
1992; 148: 597-603  
PubMed

54    Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 2006; 65 Suppl 3: iii61-
        iii64  
PubMed   DOI

55    Chen Q, Carroll HP, Gadina M. The newest interleukins: recent additions to the ever-growing cytokine family. Vitam
        Horm
2006; 74: 207-228  
PubMed   DOI

56    Cagnard N, Letourneur F, Essabbani A, Devauchelle V, Mistou S, Rapinat A, Decraene C, Fournier C, Chiocchia G.
        Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro
        cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur Cytokine Netw 2005; 16: 289-292  
PubMed

57    Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA,
        van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 2006; 103: 3298-
        3303  
PubMed   DOI

58    Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, Yamamoto K. Interactions between IL-32 and tumor
        necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther 2006; 8: R166

        PubMed   DOI

59    Kundu M, Basu J. IL-32: an emerging player in the immune response network against tuberculosis? PLoS Med 2006; 3:
        e274  
PubMed   DOI

60    Netea MG, Azam T, Lewis EC, Joosten LA, Wang M, Langenberg D, Meng X, Chan ED, Yoon DY, Ottenhoff T, Kim SH,
        Dinarello CA. Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-
        gamma-dependent mechanism. PLoS Med 2006; 3: e277  
PubMed   DOI

61    Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y, Andoh A.
        Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 2007; 149: 480-486

        PubMed   DOI

62    Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S, Izuhara K. Involvement of IL-32 in activation-induced cell death
        in T cells. Int Immunol 2006; 18: 233-240  
PubMed   DOI

63    Netea MG, Lewis EC, Azam T, Joosten LA, Jaekal J, Bae SY, Dinarello CA, Kim SH. Interleukin-32 induces the
        differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA 2008; 105: 3515-3520  
PubMed 

64    Nishida A, Andoh A, Shioya M, Kim-Mitsuyama S, Takayanagi A, Fujiyama Y. Phosphatidylinositol 3-kinase/Akt signaling
        mediates interleukin-32alpha induction in human pancreatic periacinar myofibroblasts. Am J Physiol Gastrointest Liver
        Physiol
2008; 294: G831-G838  
PubMed   DOI

65    Peyrin-Biroulet L, Vignal C, Dessein R, Simonet M, Desreumaux P, Chamaillard M. NODs in defence: from vulnerable
        antimicrobial peptides to chronic inflammation. Trends Microbiol 2006; 14: 432-438  
PubMed   DOI

66    Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V,
        Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G.
        Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603

        PubMed   DOI

67    Hugot JP. CARD15/NOD2 mutations in Crohn's disease. Ann N Y Acad Sci 2006; 1072: 9-18   PubMed   DOI

68    Netea MG, Ferwerda G, de Jong DJ, Jansen T, Jacobs L, Kramer M, Naber TH, Drenth JP, Girardin SE, Kullberg BJ,
        Adema GJ, Van der Meer JW. Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the
        induction of cytokine release. J Immunol 2005; 174: 6518-6523   PubMed   DOI

69    Netea MG, Kullberg BJ, de Jong DJ, Franke B, Sprong T, Naber TH, Drenth JP, Van der Meer JW. NOD2 mediates anti-
        inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 2004; 34: 2052-2059

        PubMed   DOI

70    Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, Eckmann L, Karin M. Nod2 mutation in Crohn's disease
        potentiates NF-kappaB activity and IL-1beta processing. Science 2005; 307: 734-738   PubMed   DOI

71    Michelsen KS, Arditi M. Toll-like receptors and innate immunity in gut homeostasis and pathology. Curr Opin Hematol
        2007; 14: 48-54   PubMed   DOI

72    Berrebi D, Maudinas R, Hugot JP, Chamaillard M, Chareyre F, De Lagausie P, Yang C, Desreumaux P, Giovannini M,
        Cezard JP, Zouali H, Emilie D, Peuchmaur M. Card15 gene overexpression in mononuclear and epithelial cells of the
        inflamed Crohn's disease colon. Gut 2003; 52: 840-846   PubMed   DOI

73    Rosenstiel P, Fantini M, Brautigam K, Kuhbacher T, Waetzig GH, Seegert D, Schreiber S. TNF-alpha and IFN-gamma
        regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003; 124:
        1001-1009   PubMed   DOI

74    Kim JM, Eckmann L, Savidge TC, Lowe DC, Witthoft T, Kagnoff MF. Apoptosis of human intestinal epithelial cells after
        bacterial invasion. J Clin Invest 1998; 102: 1815-1823   PubMed   DOI

 

S- Editor  Li DL    L- Editor  Roberts SE    E- Editor  Ma WH

 

 

 

 

 

Reviews Add
more>>


Related Articles:
Synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting
Non-invasive investigation of inflammatory bowel disease
Fertility and pregnancy in inflammatory bowel disease
Prevalence, predictors, and clinical consequences of medical adherence in IBD: How to improve it?
Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease
more>>